Miplyffa Patient Assistance Program

(arimoclomol)

Key Takeaways

  1. Miplyffa® (arimoclomol) is an oral prescription medication approved, in combination with miglustat, for the treatment of Niemann-Pick disease type C (NPC) in adults and pediatric patients 2 years of age and older.
  2. Miplyffa is a heat shock protein (HSP) amplifier that helps support cellular protein homeostasis, although its precise mechanism of clinical benefit in NPC has not been fully established.
  3. Miplyffa does not carry an FDA Boxed Warning, but treatment requires monitoring for gastrointestinal side effects, weight loss, hypersensitivity reactions, and appropriate dosing in patients with renal impairment.
  4. Prescription Hope may help eligible individuals access manufacturer-sponsored patient assistance programs that can make Miplyffa more affordable.

 

Introduction

Niemann-Pick disease type C (NPC) is a rare, progressive genetic disorder that affects the body’s ability to transport lipids within cells. Over time, this leads to neurological symptoms and other complications that require specialized, long-term medical care.

Miplyffa is an oral prescription medication approved for use in combination with miglustat to help manage Niemann-Pick disease type C in adults and children 2 years and older. As part of a comprehensive treatment strategy, it is intended to address disease progression while helping preserve neurologic function in appropriate patients.

Prescription assistance programs, such as those accessible through Prescription Hope, may help eligible patients obtain Miplyffa at a more affordable cost.

What Is the Miplyffa Patient Assistance Program?

Understanding Miplyffa Prescription Assistance

Those looking for help paying for Miplyffa or Miplyffa prescription assistance may have come across something called the Miplyffa patient assistance program.

But what is a patient assistance program?

Some pharmaceutical manufacturers recognize the financial strain that name-brand medications place on struggling Americans, and have come up with a solution to help. Qualified patients can access the name-brand medication they need at a much lower cost than retail price.

However, some patients have given up applying because patient assistance programs have been known to require extensive documentation and coordination with the patient, the pharmaceutical manufacturer, and the patient’s healthcare provider. This can lead to frustration and a sense of overwhelm.

But Prescription Hope can help!

How Expert Advocates Help Make Miplyffa More Affordable

Personalized Medication Assistance

Prescription Hope offers qualified patients access to name-brand medication for just a fraction of the retail cost. Our patient support services help qualified patients with both program admission and administrative tasks necessary to keep prescription access through a patient assistance program.

Our patient support services include managing forms, documents, and signatures, communication with healthcare providers, coordinating with manufacturers, and more.

Ongoing Patient Support

Prescription Hope is there for qualified patients throughout the admission process and into long-term medication assistance. Our team is ready to walk with you through your treatment continuity, assisting with any bookwork needed to keep patients in the programs they need. Some of the tasks we can help with include refill scheduling, document updates, yearly renewals, program monitoring, and more.

Miplyffa Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$40,830.72

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Rare Disease Treatment Costs

Even though navigating rare disease medication affordability can be difficult, your Miplyffa cost assistance solution doesn’t have to be. Rare disease medication affordability is just one of the services that Prescription Hope offers to our qualified patients.

Prescription Hope’s list of hundreds of available brand-name medications means qualified patients can access those meds for the low cost of $70.00 per month, per medication. There are no hassles, hidden fees, medication costs, or add-ons.

Patients who do not qualify for a patient assistance program can still get prescription cost solutions through us. Our team of patient advocates will diligently help you find alternative ways to save on your brand-name medication, such as substitute medications, discount cards, and coupons. If we can’t help you save money, then you pay us nothing.

Miplyffa Patient Assistance Eligibility

General Eligibility Requirements

Requirements for prescription assistance eligibility vary by patient assistance program. Wondering who qualifies for Miplyffa assistance? You may benefit from enrolling with Prescription Hope to determine whether they qualify.

All programs use criteria under certain general categories. Some of these include:

Income: All patient assistance programs have different criteria based on a range of income a patient must meet to qualify.

Insurance: All patient assistance programs also have different criteria for what a patient’s insurance coverage status must be for qualification.

Prescription: Patients must have a valid prescription for the name-brand medication they are applying for to qualify.

U.S. Residency: Patients must be legal residents of the United States to qualify.

Simple Enrollment With Expert Support

Getting Started With Enrollment

Are you looking for prescription support services? Do you need to enroll in Miplyffa assistance? Access to Prescription Hope’s medication assistance enrollment takes 6 simple steps:

  1. Submit Information: Fill out our online enrollment form in just a few minutes.
  2. Advocate Contact: After we receive your form, a patient advocate will contact you in 1-2 business days.
  3. Document Collection: Our team will collect all your documents after your prequalification.
  4. Provider Coordination: Our team will also collect any needed signatures from your healthcare provider.
  5. Program Submission: Once everything is collected and completed, we submit your application to the patient assistance program on your behalf and continue to coordinate with the pharmaceutical manufacturer.
  6. Medication Delivery: Once approved, patients normally receive their medication within 2 weeks. All medications ship directly to a patient’s door or doctor’s office.

Understanding Miplyffa

How Miplyffa Works

Miplyffa contains arimoclomol, a heat shock protein amplifier.

Arimoclomol enhances the production of heat shock proteins, which function as molecular chaperones that help proteins fold properly and maintain cellular function. In Niemann-Pick disease type C, impaired intracellular lipid trafficking leads to cellular dysfunction and progressive neurologic damage.

Although arimoclomol enhances heat shock protein production and supports cellular protein homeostasis, the precise mechanism by which it produces clinical benefit in Niemann-Pick disease type C has not been fully established.

What Conditions Does Miplyffa Treat?

Miplyffa is indicated, in combination with miglustat, for the treatment of Niemann-Pick disease type C (NPC) in adults and pediatric patients 2 years of age and older.

Miplyffa is used as part of a treatment strategy intended to address the progression of Niemann-Pick disease type C. It should be used in combination with miglustat unless miglustat is not tolerated or is contraindicated.

Benefits of Treatment

For appropriate patients with Niemann-Pick disease type C, Miplyffa may:

  • May help address the neurologic manifestations of Niemann-Pick disease type C
  • Help preserve neurologic function
  • Provide a treatment option for adults and children 2 years of age and older
  • Be used alongside miglustat as part of a disease-management strategy
  • Address a rare, progressive lysosomal storage disorder with limited treatment options

Response to treatment varies, and continued monitoring by specialists experienced in managing Niemann-Pick disease type C is recommended.

Important Safety Information and Side Effects

Miplyffa does not carry an FDA Boxed Warning.

Contraindications

The FDA Prescribing Information lists no contraindications for Miplyffa.

The most commonly reported adverse reactions include:

  • Upper respiratory tract infection
  • Diarrhea
  • Decreased weight
  • Vomiting

Additional adverse reactions observed during clinical studies included:

  • Gastrointestinal symptoms
  • Decreased appetite

Patients should notify their healthcare provider if side effects become severe, persistent, or interfere with adequate nutrition or hydration.

Patients should discuss the following with their healthcare provider:

  • Hypersensitivity reactions
  • Gastrointestinal adverse reactions, including diarrhea and weight loss
  • The importance of taking Miplyffa with miglustat, unless miglustat cannot be used because it is contraindicated or not tolerated
  • Appropriate dosage adjustments for patients with renal impairment
  • The need for regular body weight monitoring because clinically significant weight loss may occur

Patients should be monitored for tolerability and nutritional status throughout treatment.

Available human data are insufficient to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies demonstrated developmental toxicity at clinically relevant exposures. Patients who are pregnant or planning to become pregnant should discuss the potential risks and benefits of treatment with their healthcare provider.

It is not known whether arimoclomol is present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Miplyffa and any potential adverse effects on the breastfed child.

No clinically significant drug interactions are identified in the FDA Prescribing Information. Patients should inform their healthcare provider about all prescription medications, over-the-counter products, and supplements before beginning treatment.

Miplyffa is administered orally as capsules and is taken three times daily. The dosage is based on body weight and is intended to be used in combination with miglustat, unless miglustat is contraindicated or not tolerated. Capsules should be swallowed whole. For patients unable to swallow capsules, administration instructions in the FDA-approved prescribing information should be followed. Dosage adjustments are recommended for patients with renal impairment. If a dose is missed, patients should follow the FDA-approved prescribing information or contact their healthcare provider for guidance.

Access to Multiple Medications

Support Beyond Miplyffa

Patients looking for rare disease medication assistance are often looking for multiple medication assistance programs, due to their ongoing need for prescription medication access. Prescription Hope is here to help with your specialty prescription support while you focus on treatment and time with loved ones.

No matter how many patient assistance programs you qualify for, Prescription Hope offers the same medication access assistance for the same low fee of $70.00 per month, per medication.

Why Choose Prescription Hope

Patient-Focused Medication Support

For 20 years, Prescription Hope has provided prescription affordability support and patient-centered prescription help to qualified patients across the nation. We’re proud to say we offer Miplyffa assistance through Prescription Hope.

Simplified Access to Prescription Medications

Medication access support through Prescription Hope is available to qualified patients for just $70.00 per month, per medication, with no add-ons, hidden charges, or medication costs. As always, if our team of dedicated patient advocates cannot help you save money on your brand-name medication, you pay us nothing.

Ongoing Prescription Assistance

Prescription Hope’s help doesn’t end at medication assistance support. We offer long-term medication support, helping you handle administrative tasks such as refill scheduling, yearly renewals, document updates, program monitoring, and more.

Network Access

Prescription Hope leverages a network across America, providing qualified patients from rural areas to the big cities access to the name-brand medication they need for a lower cost than retail price.

If you need help with the Miplyffa Patient Assistance Program and you’re not sure where to start, enroll with Prescription Hope to see how we can help you save money today!

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!